Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer
Chimeric antigen receptor (CAR)-expressing T cells have demonstrated potent clinical efficacy in patients with B cell malignancies. However, the use of CAR-T cell therapy targeting other cancers has, in part, been limited by both the induction of antigen-specific toxicities targeting normal tissues...
Gespeichert in:
| Veröffentlicht in: | Discovery medicine 2014-11, Vol.18 (100), p.265-271 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 271 |
|---|---|
| container_issue | 100 |
| container_start_page | 265 |
| container_title | Discovery medicine |
| container_volume | 18 |
| creator | Magee, Michael S Snook, Adam E |
| description | Chimeric antigen receptor (CAR)-expressing T cells have demonstrated potent clinical efficacy in patients with B cell malignancies. However, the use of CAR-T cell therapy targeting other cancers has, in part, been limited by both the induction of antigen-specific toxicities targeting normal tissues expressing the target-antigen, and the extreme potency of CAR-T cell treatments resulting in life-threatening cytokine-release syndromes. Herein, we discuss toxicities associated with CAR-T cell therapy in the clinic. Further, we discuss potential clinical interventions to ameliorate these toxicities and the application of preclinical animal models to predict the clinical utility of CAR-T cell therapy. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1628526780</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1628526780</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-f9a6d9d67f5bbc6b7e03f7e95f6e5af01cdbf2b9bfb60aef62d34edff6e80c093</originalsourceid><addsrcrecordid>eNo1j01LAzEYhIMgtlb_guRYDwvZZJNsjmXRKhQEqeclH2-6K_tlkj3037tiCwNzmIdh5gatc1UUmVSMrNB9jN-EsJKV_A6tKC8WCblG-6rRXQfDCSJOI7ZN20NoLdZDak8w4AAWpjQGvK12n8_ZEVvoOpwaCHo6Y78EVg8WwgO69bqL8HjxDfp6fTlWb9nhY_9e7Q7ZRPM8ZV5p4ZQT0nNjrDASCPMSFPcCuPYkt854apTxRhANXlDHCnB-iUtiiWIbtP3vncL4M0NMdd_Gv016gHGOdS5oyamQJVnQpws6mx5cPYW21-FcX8-zX-DXVWo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1628526780</pqid></control><display><type>article</type><title>Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Magee, Michael S ; Snook, Adam E</creator><creatorcontrib>Magee, Michael S ; Snook, Adam E</creatorcontrib><description>Chimeric antigen receptor (CAR)-expressing T cells have demonstrated potent clinical efficacy in patients with B cell malignancies. However, the use of CAR-T cell therapy targeting other cancers has, in part, been limited by both the induction of antigen-specific toxicities targeting normal tissues expressing the target-antigen, and the extreme potency of CAR-T cell treatments resulting in life-threatening cytokine-release syndromes. Herein, we discuss toxicities associated with CAR-T cell therapy in the clinic. Further, we discuss potential clinical interventions to ameliorate these toxicities and the application of preclinical animal models to predict the clinical utility of CAR-T cell therapy.</description><identifier>EISSN: 1944-7930</identifier><identifier>PMID: 25425467</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Clinical Trials as Topic ; Humans ; Immunotherapy, Adoptive ; Models, Immunological ; Neoplasms - immunology ; Neoplasms - therapy ; Receptors, Antigen, T-Cell - immunology ; T-Lymphocytes - immunology</subject><ispartof>Discovery medicine, 2014-11, Vol.18 (100), p.265-271</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25425467$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magee, Michael S</creatorcontrib><creatorcontrib>Snook, Adam E</creatorcontrib><title>Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer</title><title>Discovery medicine</title><addtitle>Discov Med</addtitle><description>Chimeric antigen receptor (CAR)-expressing T cells have demonstrated potent clinical efficacy in patients with B cell malignancies. However, the use of CAR-T cell therapy targeting other cancers has, in part, been limited by both the induction of antigen-specific toxicities targeting normal tissues expressing the target-antigen, and the extreme potency of CAR-T cell treatments resulting in life-threatening cytokine-release syndromes. Herein, we discuss toxicities associated with CAR-T cell therapy in the clinic. Further, we discuss potential clinical interventions to ameliorate these toxicities and the application of preclinical animal models to predict the clinical utility of CAR-T cell therapy.</description><subject>Animals</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Immunotherapy, Adoptive</subject><subject>Models, Immunological</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Receptors, Antigen, T-Cell - immunology</subject><subject>T-Lymphocytes - immunology</subject><issn>1944-7930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j01LAzEYhIMgtlb_guRYDwvZZJNsjmXRKhQEqeclH2-6K_tlkj3037tiCwNzmIdh5gatc1UUmVSMrNB9jN-EsJKV_A6tKC8WCblG-6rRXQfDCSJOI7ZN20NoLdZDak8w4AAWpjQGvK12n8_ZEVvoOpwaCHo6Y78EVg8WwgO69bqL8HjxDfp6fTlWb9nhY_9e7Q7ZRPM8ZV5p4ZQT0nNjrDASCPMSFPcCuPYkt854apTxRhANXlDHCnB-iUtiiWIbtP3vncL4M0NMdd_Gv016gHGOdS5oyamQJVnQpws6mx5cPYW21-FcX8-zX-DXVWo</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Magee, Michael S</creator><creator>Snook, Adam E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20141101</creationdate><title>Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer</title><author>Magee, Michael S ; Snook, Adam E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-f9a6d9d67f5bbc6b7e03f7e95f6e5af01cdbf2b9bfb60aef62d34edff6e80c093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Immunotherapy, Adoptive</topic><topic>Models, Immunological</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Receptors, Antigen, T-Cell - immunology</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magee, Michael S</creatorcontrib><creatorcontrib>Snook, Adam E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Discovery medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magee, Michael S</au><au>Snook, Adam E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer</atitle><jtitle>Discovery medicine</jtitle><addtitle>Discov Med</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>18</volume><issue>100</issue><spage>265</spage><epage>271</epage><pages>265-271</pages><eissn>1944-7930</eissn><abstract>Chimeric antigen receptor (CAR)-expressing T cells have demonstrated potent clinical efficacy in patients with B cell malignancies. However, the use of CAR-T cell therapy targeting other cancers has, in part, been limited by both the induction of antigen-specific toxicities targeting normal tissues expressing the target-antigen, and the extreme potency of CAR-T cell treatments resulting in life-threatening cytokine-release syndromes. Herein, we discuss toxicities associated with CAR-T cell therapy in the clinic. Further, we discuss potential clinical interventions to ameliorate these toxicities and the application of preclinical animal models to predict the clinical utility of CAR-T cell therapy.</abstract><cop>United States</cop><pmid>25425467</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1944-7930 |
| ispartof | Discovery medicine, 2014-11, Vol.18 (100), p.265-271 |
| issn | 1944-7930 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1628526780 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Animals Clinical Trials as Topic Humans Immunotherapy, Adoptive Models, Immunological Neoplasms - immunology Neoplasms - therapy Receptors, Antigen, T-Cell - immunology T-Lymphocytes - immunology |
| title | Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T11%3A41%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Challenges%20to%20chimeric%20antigen%20receptor%20(CAR)-T%20cell%20therapy%20for%20cancer&rft.jtitle=Discovery%20medicine&rft.au=Magee,%20Michael%20S&rft.date=2014-11-01&rft.volume=18&rft.issue=100&rft.spage=265&rft.epage=271&rft.pages=265-271&rft.eissn=1944-7930&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1628526780%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1628526780&rft_id=info:pmid/25425467&rfr_iscdi=true |